Johnson & Johnson (NYSE:JNJ) Shares Acquired by Coastline Trust Co

Coastline Trust Co increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,476 shares of the company’s stock after purchasing an additional 687 shares during the period. Coastline Trust Co’s holdings in Johnson & Johnson were worth $2,184,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. purchased a new position in Johnson & Johnson in the 1st quarter valued at $765,000. Empowered Funds LLC boosted its position in Johnson & Johnson by 46.7% during the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after acquiring an additional 32,244 shares during the last quarter. Alpha Family Trust grew its stake in Johnson & Johnson by 180.0% during the 1st quarter. Alpha Family Trust now owns 6,230 shares of the company’s stock valued at $986,000 after acquiring an additional 4,005 shares in the last quarter. Kingsview Wealth Management LLC raised its holdings in Johnson & Johnson by 1.1% in the 1st quarter. Kingsview Wealth Management LLC now owns 137,942 shares of the company’s stock valued at $21,821,000 after acquiring an additional 1,559 shares during the last quarter. Finally, Maple Capital Management Inc. lifted its stake in Johnson & Johnson by 2.8% in the 1st quarter. Maple Capital Management Inc. now owns 161,137 shares of the company’s stock worth $25,490,000 after purchasing an additional 4,330 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.4 %

NYSE JNJ opened at $153.99 on Friday. The firm’s fifty day moving average price is $161.35 and its 200 day moving average price is $156.02. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market capitalization of $370.75 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.66 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.22%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday. They set an “outperform” rating and a $190.00 price target for the company. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.94.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.